Does Lovaza (Omega-3 Fatty Acid Ethyl Esters - OFA) Improve Clopidogrel Associated P2Y12 Inhibition in Stroke Patients? (P03.004)

Objective: Does Lovaza have synergistic P2Y12-platelet inhibition in patients on Clopidogrel? Background The action of OFA in preventing cerebrovascular disease remains unknown. In addition to altering lipid profiles, OFA may have platelet aggregation inhibitory effects as previously reported. Clopidogrel inhibits platelets via the P2Y12-receptor. The P2Y12-inhibiton is measured to determine clopidogrel effectiveness using the VerifyNow analyzer. OFAs may alter clopidogrel associated platelet inhibition via a possible synergistic effect on P2Y12-inhibition. The purpose of this study was to determine whether OFA could improve the P2Y12-inhibition in patients with low percentage of platelet-inhibition after a loading dose (300 or 600mg) of clopidogrel. Design/Methods: This is a retrospective single center study of 1794 inpatients with cardio/cerebrovascular disease, including stroke/TIA, and on clopidogrel regime. The exclusion criteria were: patients on OFA before the P2Y12-inhibition test, whose clopidogrel response tests were done prior or Results: Patients who converted to a >20%P2Y12-inhibition in the lovaza+clopidogrel group was 69.23%(18/26) while the clopidogrel alone group was 73.33%(22/30), with no statistical difference noted (p>0.05). Also computed was the average change in percent inhibition between the two groups. The lovaza+clopidogrel group had an average change in percent inhibition of 21.74%, while the clopidogrel alone group had an average change of 23.07%, with no significant difference between groups (p>0.05). Conclusions: This study did not find additional P2Y12 platelet-inhibition but OFAs might inhibit platelet aggregation through other mechanisms. Disclosure: Dr. Li has nothing to disclose. Dr. Li has nothing to disclose. Dr. Baxter has nothing to disclose. Dr. Mehta has received personal compensation for activities with Biogen Idec, Teva, and Gerson Lehrman Group as a consultant or speaker.